- CEO
- Christopher Devall
- Full Time Employees
- 2
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 78 SW 7th Street Miami FL United States of America 33130
- IPO Date
- Aug 30, 2024
- Business
- SIM Acquisition Corp. I (SIMA), a Cayman Islands exempted company founded in 2024 and headquartered at 78 SW 7th Street, Suite 500, Miami, Florida, operates as a blank check company, or special purpose acquisition company (SPAC), with no significant ongoing business operations; it focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more private companies, primarily targeting high-quality, growth-oriented businesses in the healthcare sector. The company offers Class A ordinary shares (NASDAQ: SIMA), redeemable warrants (NASDAQ: SIMAW), and units comprising one Class A ordinary share and one-half of one redeemable warrant (NASDAQ: SIMAU); it maintains a trust account holding proceeds from its securities offerings, invested in U.S. money market funds, for deployment in a business combination, while providing public shareholders redemption rights prior to any such transaction. SIMA conducts its activities through a management team led by Chairman and CEO Erich L. Spangenberg and CFO and Director David Kutcher, supported by directors including Dr. Toby Cosgrove, former CEO of the Cleveland Clinic, Janine Grasso, and Vince Capone, with operations centered in the United States as a subsidiary of SIM Sponsor 1 LLC. In July 2024, SIMA completed a $230 million initial public offering of 23 million units at $10.00 per unit, including the full exercise of underwriters' over-allotment option, alongside a simultaneous private placement of 6 million warrants to its sponsor and Cantor Fitzgerald & Co. at $1.00 each; transaction costs totaled approximately $15.4 million, including underwriting fees. As of late 2025, SIMA reports quarterly earnings, files ongoing SEC disclosures such as 10-Q and 13G/A forms, and has drawn institutional interest including a recent purchase of 50,000 shares by BCK Capital Management LP, while continuing to seek a healthcare target within its 24-month combination period ending July 2026, with no business combination announced to date.